Effectiveness of Mirror Therapy in Patients With Amputations of Lower Limbs of Vascular Origin

NCT ID: NCT03149432

Last Updated: 2019-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-22

Study Completion Date

2019-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to assess the efficacy of the mirror therapy on phantom pain for patients with amputation after vascular etiology. the secondary aim are to measure the impact of the mirror therapy on quality of life, sleep disorders, and predictive factors for effectiveness. the design is a prospective study, randomised, blindly evaluated, monocentric. There will be 2 groups: 1) rehabilitation and gabapentine; 2) rehabilitation and gabapentine + mirror therapy during the first 4 weeks. The assessment are going to be preformed at the inclusion day and then every 2 weeks during 8 weeks. the primary evaluation criterion will be the phantom pain measured on a VAS. the delay for inclusion is 18 months in order ton include 40 patients. The length of the study is 20 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Several variables at the beginning collected to study the predictive factors of effectiveness of mirror therapy:

* Age
* Sex
* Delay from amputation
* Etiology: neuropathy associated or not
* VAS of preoperative pain
* VAS phantom pain at baseline
* Localization of pain
* Ability to mobilize the phantom limb
* Healing obtained or not
* Type of stump: defective or not
* Type of amputation
* Circumstance of amputation: programmed / not programmed
* Psychological experience: Montgomery and Asberg Depression Scale score (MADRS)
* Socio-economic level
* The initial analgesic neuropathic treatment
* Possible previous prosthesis

It was also collected at week 4 and 8 :

\- The level of advancement of the equipment by prosthesis

Each patient with the inclusion criteria, who agreed to participate in the study after reading the information note and signed consent, will be included in one of the two groups after randomization.

Group Reference Analgesic: receiving a reference antalgic management according to the protocol of the service: traditional management and treatment with Gabapentin.

Group Reference Analgesic and mirror therapy: receiving the reference antalgic management according to the protocol of the service: traditional management and treatment with Gabapentin as well as a management by mirror therapy during the first 4 weeks.

In group Reference analgesic and Mirror therapy, the mirror therapy will be performed by a physiotherapist trained in practice and already applying this technique in the center. Each patient receives, during the first week of treatment, 5 sessions of 20 minutes each decomposed as follows: 15 minutes of motor exercise and 5 minutes of sensory exercise. The content of the session was decided and put in place by the physiotherapist.

During the following 3 weeks the patients must practice self-rehabilitation at the rate of 5 sessions per week with a weekly re-evaluation session by the physiotherapist.

Before inclusion, the patient should be weaned as far as possible from neuropathic neuropathic treatments other than Gabapentin introduced for the treatment of phantom pain.

In both groups, patients receive the reference treatment according to the protocol of the service: titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks.

Thereafter, depending on the patient's response and tolerance, the dose may be increased in increments of 300 mg / day every 2-3 days to a maximum dose of 3600 mg / day. A slower titration of gabapentin may be appropriate in some patients. The minimum time to reach a dose of 1800 mg / day is one week, to reach 2400 mg / day it is 2 weeks in total and to reach 3600 mg / day it is 3 weeks in total.

No other analgesic neuropathic treatment could be introduced or increased (PREGABALINE, AMITRIPTYLINE, DULOXETINE, MORPHINIC).

A punctual treatment (PARACETAMOL, CODEINE, NSAID, NEFOPAM) on acute pain without action on neuropathic type pain, linked to a different pathology is allowed.

If in Reference Analgesic group, the phantom limb pain was not sufficiently relieved at the end of the protocol, and the mirror therapy seems to be effective, a treatment by mirror therapy can be proposed to them.

The VAS and the details of the analgesic treatment will be collected every 2 weeks, blinded by an independent evaluator. Patients should not tell the evaluator which group they are assigned to.

The advancement of the prosthesis were collected at 4 and 8 weeks. Moreover, this is an observational study, following routine procedures already practiced systematically in the institution with this patient population. There are no additional procedures for diagnosis or additional medical supervision in this study.

16 subjects per group make it possible to demonstrate a size 1 effect with a risk of first species of 5% and a power of 80%. In order to take into account the risk of exiting the trial, we plan to include 20 patients in each group, sp a total of 40 patients.

Statistical analysis will use Sigma Plot® 12.5 for Windows Systat Software, Inc. or R software. Quantitative data will be reported in terms of mean, standard deviation and / or median and interquartile range. Qualitative data will be reported in terms of numbers and percentages.

The groups will be compared by Chi2 tests, or Fisher tests in case of insufficient numbers, for the qualitative variables. For quantitative variables the groups will be compared by T tests, or Wilcoxon tests if the variables do not have a normal distribution.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amputation Phantom Pain Following Amputation of Lower Limb

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors
The assossor won't know if the participant has received the mirror therapy

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Reference analgesic

Gabapentin Rehabilitation Local care

Group Type ACTIVE_COMPARATOR

Gabapentin

Intervention Type DRUG

titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks

Rehabilitation

Intervention Type PROCEDURE

Daily care with physiotherapist ; orthoprosthetists , and specialized sports educators ; if necessary : occupational therapy.

Local care

Intervention Type OTHER

local care for directed healing of the stump.

reference analgesic and mirror therapy

Mirror Therapy Gabapentin Rehabilitation Local care

Group Type EXPERIMENTAL

Mirror Therapy

Intervention Type PROCEDURE

by a mirror effect the patient sees his remaining arm at the place of the amputated arm that cause an illusion of presence of this arm to the brain and would have an effect of reducing phantom pain

Gabapentin

Intervention Type DRUG

titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks

Rehabilitation

Intervention Type PROCEDURE

Daily care with physiotherapist ; orthoprosthetists , and specialized sports educators ; if necessary : occupational therapy.

Local care

Intervention Type OTHER

local care for directed healing of the stump.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mirror Therapy

by a mirror effect the patient sees his remaining arm at the place of the amputated arm that cause an illusion of presence of this arm to the brain and would have an effect of reducing phantom pain

Intervention Type PROCEDURE

Gabapentin

titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks

Intervention Type DRUG

Rehabilitation

Daily care with physiotherapist ; orthoprosthetists , and specialized sports educators ; if necessary : occupational therapy.

Intervention Type PROCEDURE

Local care

local care for directed healing of the stump.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient over 18 years of age who signed the memorandum.
* Patient hospitalized in the service for setting up equipment.
* In the aftermath of a major amputation of the lower limb, of vascular origin.
* Patients with phantom pain greater than or equal to 30 Visual Analog Evaluation (EVA); Whether pharmacologically or not.

Exclusion Criteria

* Refusal to participate in the study.
* Presence of cognitive or psychiatric disorders that compromise the realization of mirror therapy.
* Presence of neurological, rheumatological or orthopedic disorders that may prevent movement of the unaffected limb.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre d'Investigation Clinique et Technologique 805

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Larlène Lacout, MD

Role: PRINCIPAL_INVESTIGATOR

APHP

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institut Merle d'Aubigné

Valenton, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

B Aledi L, Flumignan CD, Trevisani VF, Miranda F Jr. Interventions for motor rehabilitation in people with transtibial amputation due to peripheral arterial disease or diabetes. Cochrane Database Syst Rev. 2023 Jun 5;6(6):CD013711. doi: 10.1002/14651858.CD013711.pub2.

Reference Type DERIVED
PMID: 37276273 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2016-A00771-50

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

VR to Evaluate Phantom Limb Pain
NCT05915065 ACTIVE_NOT_RECRUITING NA
Prophylactic TBR on Phantom Limb Pain
NCT06956508 NOT_YET_RECRUITING NA